ABCA4 and severe early-childhood-onset retinal dystrophy: An ongoing multicenter open-label phase II clinical trial (STARLIGHT, NCT05417126) is being conducted to evaluate the safety and efficacy of a single intravitreal injection of vMCO-010 in up to six subjects with STGD due to ABCA4, ELOVL4, or PROM1 mutations and visual acuity worse than 20/640 (Table 1A).